Drugs / MSCs-Exos
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04388982 | Jul 2020 → Aug 2021 | Alzheimer disease | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCs-Exos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04388982 ↗ |
| Known as | ahaMSCs-Exos | “AIMS: The first three-arm, drug-intervention, phase I/II clinical trial was conducted to explore the safety and efficacy of allogenic human adipose MSCs-Exos (ahaMSCs-Exos) in...” PMID 37859748 ↗ Oct 2023 |
| Modality | Other / unclassified | “Exosomes are naturally occurring nanosized vesicles” NCT04388982 ↗ |
| Route | Intranasal | “intranasally administrated with ahaMSCs-Exos” PMID 37859748 ↗ Oct 2023 |